Apo(a) size and PAD revascularisation outcomes: What’s the link?Lepodisiran: What progress towards Lp(a) reduction?Phase 1 data show sustained Lp(a) reduction with lepodisiran Heart-1 trial: Interim data show PCSK9 gene editing lowers LDL-C Small apoA isoforms linked to worse PAD revascularisation outcomes OCEAN(a)-DOSE study highlights Lp(a) variability with time

From the Editors

Posted on 18 March 2014 |

MK-0616 - How near is an oral PCSK9i?

John chapman & Chris Packard Professors John Chapman and Chris Packard consider the evidence supporting MK-0616 as potentially the first oral PCSK9i to reach the clinic.

Read the editorial

MK-0616: Hope for an oral PCSK9 inhibitor?

Related content

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters